Neogen launches ELISA test for dermorphin

Neogen has introduced an ELISA screening test that offers ultra-sensitive detection of dermorphin, which has been shown to produce both analgesic effects and hyperactivity in horses.

Dermorphin is an opioid peptide that is isolated from skin secretions of South American tree frogs in the Phyllomedusa genus, and has been shown to have 30 to 40 times the effect of morphine. Use of dermorphin was first detected in the racing industry in 2011, and the Association of Racing Commissioners International, Inc., classified dermorphin as a Class 1 prohibited substance in July 2011.

Neogen’s new simple, sensitive and fast Dermorphin ELISA test kit has been validated for use with equine urine, serum and plasma, and canine urine, samples. The assay offers extreme sensitivity without the need for significant sample preparation. The new test kit is compatible with automated and semi-automated instruments.

“We are very pleased to provide a simple, quick and accurate method to screen samples for this emerging performance-enhancing drug,” said Neogen’s Emilie Stanley. “Our new test adds to the comprehensive line of assays to detect more than 300 major drug analytes and metabolites that we have developed in our more than 30 years in business.”

For more information on Neogen’s racing and forensic toxicology test kits, visit www.neogen.com, or click here.

Comments are closed.